Dupilumab in atopic dermatitis: Review of data and clinical experience; Дупилумаб при атопическом дерматите: обзор данных и опыт применения

Introduction. Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impairs patients’ quality of life. The advent of targeted biologic therapy with dupilumab has become an important milestone in the treatment of moderate-to-severe AD, as confirmed by clinical trials and real-world data. Aim. To study the dynamics of quality of life in patients with AD receiving dupilumab in real clinical practice. Materials and methods. A review of current literature, including results from clinical trials and registry data, was conducted, along with an analysis of our own cohort of 38 patients with AD treated with dupilumab. The dynamics of clinical indices (EASI, SCORAD, VAS) and quality-of-life measures (DLQI in adults and CDLQI in children) were evaluated. Results. Patients’ ages ranged from 6 to 47 years (mean – 20 years), with males accounting for 65.8%. The duration of therapy ranged from 2 to 5 years (mean – 3.4 years). During treatment, the mean EASI score decreased from 39.0 to 5.2 (p < 0.0001), SCORAD from 58.7 to 11.2 (p < 0.0001), and VAS from 7.3 to 2.2 (p < 0.0001). Quality-of-life measures improved markedly: DLQI decreased from 25.1 to 2.3, and CDLQI from 21.1 to 2.4 (both p < 0.00001). These findings are consistent with international studies such as TREATgermany, BioDay, and RELIEVE-AD. Conclusion. Dupilumab demonstrates high efficacy, significant reduction in clinical manifestations, and substantial improvement in quality of life in both adults and children with AD during long-term real-world use. The combination of evidence from randomized clinical trials and real-world practice confirms that dupilumab is the treatment of choice and may be considered an optimal long-term therapeutic strategy for patients with AD. © 2025 Elsevier B.V., All rights reserved.